LUCID DIAGNOSTICS INC.
New York
About LUCID DIAGNOSTICS INC.
Lucid Diagnostics is a commercial-stage, cancer-prevention medical diagnostics company. Lucid focuses on patients with gastroesophageal disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid’s EsoGuard Esophageal DNA Test is performed on samples collected in a brief noninvasive office procedure with its EsoCheck Esophageal Cell Collection Device, a diagnostic test capable of serving as a widespread screening tool to prevent cancer and cancer deaths through early detection of esophageal precancer in at-risk GERD patients.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $102.4M
- Funding stage: IPO
- Last round: Post-IPO Equity (Sep 2025)
- Ticker: nasdaq:LUCD
- Website: luciddx.com
- Phone: (917)-813-1828
Industries & Categories
Biotechnology, Health Care, Health Diagnostics, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/lucid-diagnostics-inc-35958 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.